This indicator covers the incidence of healthcare associated infections from Methicillin-resistant Staphylococcus aureus (MRSA). It measures outcomes that reflect the quality of care or processes ...
Dalbavancin is under clinical development by AbbVie and currently in Phase III for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. According to GlobalData, Phase III drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback